文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

蒽环类药物诱导的心脏毒性——我们是否即将跨越这一障碍?

Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
PubMed 文献 · Eur J Cancer · 2023-02-24

蒽环类药物显著改善多种恶性肿瘤的总生存,但可导致急性和慢性心脏毒性,长期心脏毒性可致约三分之一患者死亡。活性氧和拓扑异构酶IIβ抑制被认为是关键机制。预防策略包括血管紧张素转换酶抑制剂、沙坦类、β受体阻滞剂、醛固酮拮抗剂、他汀类药物、铁螯合剂及开发新型蒽环类衍生物。本综述讨论临床评估过的多柔比星类似物及新型脂质体蒽环类药物L-Annamycin用于软组织肉瘤肺转移和急性髓系白血病的最新进展。

要点

  • 蒽环类是最有效的细胞抑制药物之一,但急性和慢性心脏毒性是重要挑战。
  • 活性氧和拓扑异构酶IIβ抑制被认为是蒽环类心脏毒性的关键机制。
  • 预防策略包括ACEI、沙坦类、β受体阻滞剂、醛固酮拮抗剂、他汀类、铁螯合剂及新型衍生物。

核心结论

  • 蒽环类药物治疗相关心脏毒性是亟待解决的临床问题,目前正通过药物预防和开发低心脏毒性衍生物等策略应对。

研究设计与样本

  • 综述,讨论临床评估过的多柔比星类似物及新型脂质体蒽环类药物L-Annamycin用于软组织肉瘤肺转移和急性髓系白血病的最新进展。

主要发现

  • 长期心脏毒性可导致约三分之一患者死亡。
  • 活性氧(源于蒽环类细胞内代谢)和药物诱导的拓扑异构酶IIβ抑制被认为是心脏毒性的关键机制,但部分分子通路机制尚未完全阐明。

关键数值与推荐

  • 预防策略包括:(i)血管紧张素转换酶抑制剂、沙坦类、β受体阻滞剂、醛固酮拮抗剂和他汀类药物;(ii)铁螯合剂;(iii)开发心脏毒性很小或没有心脏毒性的新型蒽环类衍生物。
  • 综述讨论了临床评估过的多柔比星类似物,这些类似物被开发为潜在无心脏毒性的抗癌药。
  • 综述纳入了新型脂质体蒽环类药物L-Annamycin用于治疗软组织肉瘤肺转移和急性髓系白血病的最新进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 部分分子通路机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anthracyclines have contributed significantly to remarkable improvements in overall survival and are regarded as the most effective cytostatic drug for cancer treatment in various malignancies. However, anthracyclines are a significant cause of acute and chronic cardiotoxicity in cancer patients, and long-term cardiotoxicity can lead to death in about one-third of patients. Several molecular pathways have been implicated in the development of anthracycline-induced cardiotoxicity, although the underlying mechanisms of some molecular pathways are not fully elucidated. It is now generally believed that anthracycline-induced reactive oxygen species (resulting from intracellular metabolism of anthracyclines) and drug-induced inhibition of topoisomerase II beta are the key mechanisms responsible for the cardiotoxicity. To prevent cardiotoxicity, several strategies are being followed: (i) angiotensin-converting enzyme inhibitors, sartans, beta-blockers, aldosterone antagonists, and statins; (ii) iron chelators; and (iii) by development of new anthracycline derivatives with little or no cardiotoxicity. This review will discuss clinically evaluated doxorubicin analogues that were developed as potentially non-cardiotoxic anticancer agents and include recent development of a novel liposomal anthracycline (L-Annamycin) for the treatment of soft-tissue sarcoma metastatic to the lung and acute myelogenous leukaemia.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dempke WCM, Zielinski R, Winkler C, et al. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle? Eur J Cancer. 2023. PMID: 36966697. doi:10.1016/j.ejca.2023.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。